Literature DB >> 33735186

Impact of 1h oral glucose tolerance test on the clinical status of adult cystic fibrosis patients over a 4-year period.

Valérie Boudreau1,2, Quitterie Reynaud3,4, Angélique Denis5,6, Johann Colomba1,2, Sandrine Touzet5,6, Katherine Desjardins1, Stéphanie Poupon Bourdy5,6, Isabelle Durieu3,4, Rémi Rabasa-Lhoret1,2,7.   

Abstract

OBJECTIVE: To report the clinical profile associated with G60 and I60 over a 4-year prospective observational period in 2 large cohorts of adult patients with CF.
METHODS: 319 patients were included (210 Canadian and 119 French) and classified according to their inclusion G60 (≥ or < 11.1 mmol/L) and the median inclusion I60 (≥ or < 24 mU/I). Forced expiratory volume in 1 second (FEV1), body mass index (BMI) were collected on OGTT days. Linear mixed regression models were used to assess the effect of G60 and I60.
RESULTS: High G60 was not associated to a lower FEV1 at inclusion and the follow-up decline was not higher in the high G60 group (Coefficient [95% CI]: -3.4 [-7.4;0.6], p = 0.0995.). There was no significant association between BMI and G60. Patients with high I60 tended to have a higher mean BMI (+0.5 kg/m2 [0.0 to 1.1], p = 0.05) but no interaction over time was observed.
CONCLUSIONS: High G60 is not associated with a lower lung function at inclusion nor its decline over a 4-year follow-up. High I60 is slightly associated to a higher weight at inclusion, but not with BMI evolution over time in adult patients.

Entities:  

Year:  2021        PMID: 33735186      PMCID: PMC7971459          DOI: 10.1371/journal.pone.0246897

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  29 in total

1.  Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET).

Authors:  Adèle Coriati; Sophie Ziai; Mirna Azar; Yves Berthiaume; Rémi Rabasa-Lhoret
Journal:  J Cyst Fibros       Date:  2015-03-27       Impact factor: 5.482

Review 2.  Screening for Cystic Fibrosis-Related Diabetes: Matching Pathophysiology and Addressing Current Challenges.

Authors:  Valérie Boudreau; Quitterie Reynaud; Catherine Lehoux Dubois; Adèle Coriati; Katherine Desjardins; Isabelle Durieu; Rémi Rabasa-Lhoret
Journal:  Can J Diabetes       Date:  2016-10       Impact factor: 4.190

3.  The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity.

Authors:  Johann Colomba; Valérie Boudreau; Catherine Lehoux-Dubois; Katherine Desjardins; Adèle Coriati; François Tremblay; Rémi Rabasa-Lhoret
Journal:  J Cyst Fibros       Date:  2019-01-30       Impact factor: 5.482

Review 4.  Diagnosing cystic fibrosis-related diabetes: current methods and challenges.

Authors:  Bernadette Prentice; Shihab Hameed; Charles F Verge; Chee Y Ooi; Adam Jaffe; John Widger
Journal:  Expert Rev Respir Med       Date:  2016-06-13       Impact factor: 3.772

5.  Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex.

Authors:  Connor Lewis; Scott M Blackman; Amanda Nelson; Ewa Oberdorfer; Daniel Wells; Jordan Dunitz; William Thomas; Antoinette Moran
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

6.  Diagnosis of cystic fibrosis-related glucose abnormalities: Can we shorten the standard oral glucose tolerance test?

Authors:  Adèle Coriati; Belinda Elisha; Sandrine Virassamynaik; Maude Phaneuf; Sophie Ziai; Marie-Soleil Gauthier; Rémi Rabasa-Lhoret
Journal:  Appl Physiol Nutr Metab       Date:  2013-06-18       Impact factor: 2.665

Review 7.  Glucose intolerance in cystic fibrosis patients.

Authors:  S Lanng
Journal:  Paediatr Respir Rev       Date:  2001-09       Impact factor: 2.726

8.  Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.

Authors:  Antoinette Moran; Carol Brunzell; Richard C Cohen; Marcia Katz; Bruce C Marshall; Gary Onady; Karen A Robinson; Kathryn A Sabadosa; Arlene Stecenko; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

9.  Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis.

Authors:  Jill Brodsky; Shayne Dougherty; Ramkrishna Makani; Ronald C Rubenstein; Andrea Kelly
Journal:  Diabetes Care       Date:  2011-01-12       Impact factor: 19.112

10.  Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.

Authors:  Antoinette Moran; Jordan Dunitz; Brandon Nathan; Asad Saeed; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

View more
  1 in total

1.  Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers.

Authors:  Laurence Weiss; Olivia Ronsin; Quitterie Reynaud; Michel Abely; Laurent Mely; Pierre-Régis Burgel; Jacques Beltrand; Laurence Kessler
Journal:  J Clin Transl Endocrinol       Date:  2022-04-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.